【TaiGen】The Company's Board of Directors Resolves to Approve the 2026 Q1 Consolidated Financial Report
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
TaiGen Biotechnology announced that its Board of Directors approved the 2026 Q1 consolidated financial report. The company reported revenue of NT$172,891 thousand, a pre-tax net loss of NT$26,215 thousand, and basic EPS of -0.45 NTD.